UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 10,920 Shares of Alector, Inc. (NASDAQ:ALEC)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC trimmed its position in shares of Alector, Inc. (NASDAQ:ALEC) by 7.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 143,061 shares of the company’s stock after selling 10,920 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.15% of Alector worth $667,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently bought and sold shares of ALEC. FMR LLC raised its holdings in Alector by 1.0% during the 3rd quarter. FMR LLC now owns 14,595,014 shares of the company’s stock worth $68,013,000 after purchasing an additional 137,794 shares during the last quarter. Valence8 US LP acquired a new stake in shares of Alector in the 3rd quarter valued at about $69,000. Charles Schwab Investment Management Inc. raised its holdings in shares of Alector by 14.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 760,606 shares of the company’s stock valued at $3,544,000 after purchasing an additional 94,145 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its position in shares of Alector by 54.7% in the third quarter. Massachusetts Financial Services Co. MA now owns 174,718 shares of the company’s stock worth $814,000 after purchasing an additional 61,798 shares in the last quarter. Finally, Intech Investment Management LLC acquired a new position in Alector during the third quarter worth $90,000. Institutional investors and hedge funds own 85.83% of the company’s stock.

Alector Price Performance

Shares of NASDAQ:ALEC opened at $1.86 on Friday. The company has a market capitalization of $182.16 million, a P/E ratio of -1.09 and a beta of 0.51. The business’s 50 day simple moving average is $3.82 and its 200 day simple moving average is $4.66. Alector, Inc. has a 1 year low of $1.73 and a 1 year high of $8.90.

Alector (NASDAQ:ALEC) last released its earnings results on Wednesday, November 6th. The company reported ($0.43) EPS for the quarter, beating the consensus estimate of ($0.53) by $0.10. Alector had a negative net margin of 257.54% and a negative return on equity of 108.77%. The firm had revenue of $15.34 million for the quarter, compared to analyst estimates of $16.33 million. On average, sell-side analysts anticipate that Alector, Inc. will post -1.85 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently commented on ALEC shares. BTIG Research reduced their price target on Alector from $16.00 to $5.00 and set a “buy” rating for the company in a research report on Tuesday, November 26th. HC Wainwright decreased their price objective on shares of Alector from $35.00 to $7.00 and set a “buy” rating for the company in a research report on Friday, November 29th. Stifel Nicolaus cut Alector from a “buy” rating to a “hold” rating and set a $4.00 price target for the company. in a report on Monday, December 16th. Cantor Fitzgerald restated an “overweight” rating on shares of Alector in a research note on Tuesday, November 26th. Finally, Bank of America cut Alector from a “neutral” rating to an “underperform” rating and reduced their price objective for the stock from $9.00 to $1.00 in a report on Wednesday, December 4th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $3.75.

Insider Buying and Selling at Alector

In other Alector news, CFO Marc Grasso sold 16,489 shares of the firm’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $2.52, for a total value of $41,552.28. Following the sale, the chief financial officer now owns 330,651 shares in the company, valued at $833,240.52. This trade represents a 4.75 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Arnon Rosenthal sold 52,172 shares of the business’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $2.52, for a total transaction of $131,473.44. Following the sale, the chief executive officer now directly owns 2,507,074 shares in the company, valued at approximately $6,317,826.48. The trade was a 2.04 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 95,161 shares of company stock valued at $239,806. 9.10% of the stock is currently owned by corporate insiders.

Alector Profile

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.